Roots Analysis has done a detailed study on STING Pathway Targeting Therapeutics and Technologies, 2020-2030.” covering key aspects of the industry and identifying future growth opportunities.

To order this 310+ page report, which features 150+ figures and 200+ tables, please visit this link

Key Market Insights
 Many small / macro molecule-based STING pathway modulators are currently being evaluated as monotherapies as well as in combination with other drugs
 The pipeline features candidates targeting different therapeutic areas and designed for administration through a variety of routes; majority of such therapeutics are being developed as third-line and second-line treatments
 In recent years, several well funded start-ups have entered this field of research, and are gradually developing proprietary products based on the STING pathway for the treatment of a variety of indications
 In addition, a number of big pharmaceutical players have also partnered with developers focused on STING targeting molecules in order to expand their respective capabilities in this upcoming field of pharmacology
 Published scientific literature indicates that both industry and academic players have made equal contributions to the innovation in this field; the major focus of such studies is presently on anti-cancer therapeutics
 Several non-profit organizations have extended financial support to aid research efforts in this domain; the current focus appears to be on drug development and disease modelling studies
 Foreseeing a lucrative future, private and public investors have invested capital worth over USD 2.5 billion, across more than 80 instances, in companies involved in STING pathway research
 The rising interest is also reflected in recent partnership activity, involving the active participation of both international and indigenous companies; majority of the deals have been focused on novel technology platforms
 Multiple companies are developing novel technology platforms for enhancing the research and development of STING pathway targeting therapeutics
 Technology developers are expected to continue relying on licensing agreements involving different STING modulators as their primary source of revenues in the foreseen future

For more information, please visit https://www.rootsanalysis.com/reports/sting-pathway-targeting-thera...

Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
[email protected]